The Board reviewed and discussed the key aspects of the CEO monthly report and supporting papers, including the Board Strategic Scorecard Report, which had been circulated prior to the meeting.
The CEO advised the Board that his first weeks as CEO have had a strong focus on engaging with as many of the frontline staff, service partners and managers, which has been centred on listening to and understanding the challenges, opportunities and innovations with a view to being better able to support them going forward. He informed the Board that he met with colleagues from a variety of service areas such as Disability Services, including voluntary service colleagues, Older Persons Services, Ambulance Services and Acute Service, including professional groups, and intends to seek out opportunities to engage with all of these stakeholders in the weeks and months ahead.
The CEO welcomed the appointment of Mr Damien McCallion as Chief Operations Officer (COO) and Ms Mairead Dolan as Interim CFO.
An update was provided in relation to the Monkeypox infection and the Board were advised that the National Crisis Management Team (NCMT) is overseeing and co-ordinating the HSE’s ongoing response. A wider vaccination programme commenced on 17 October 2022 to target up to 3,000 people for vaccination. The vaccination programme includes plans to extend vaccination coverage where additional supplies are received.
National Genetics and Genomics Strategy
The CEO updated the Board in relation to this area, and acknowledged the work done by CCO which will be brought to the Safety & Quality Committee, EMT and Board by the end of the year. A discussion took place in relation to the Strategy and recent correspondence received from IPPOSI to which a response had issued from the CCO, and that the recommendations from the Citizen Jury which were welcomed. The patient involvement in the Strategy was discussed. The Board were informed that there was patient involvement in the Strategy development, both on the steering group and subgroups. It was suggested that feedback be obtained from the Personal and Public Involvement (PPI) representatives on their experience with the strategy development process in order to learn from it and improve the PPI experience in the area in future.
Test & Trace
ND T&T provided an update to the Board in relation to the transition to the future clinical, public health and surveillance led model, including the engagement with the DoH in relation to the agreed date for the implementation of the new Public Health guidance and ensuring that the appropriate planning and stakeholder engagement is in place before commencing the transition to the future model.
She noted the focus is on finalising the operational surge response and emergency response plans should either scenario emerge, as well as preparing readiness plans to gradually move from the existing model towards the clinically driven and surveillance-led model. She advised the Board that over the last week there was a slight downward trend in demand relative to the previous week, noting that community and GP referrals, laboratory tests and antigen test kits booked have all decreased.
The Board discussed the aligned Flu and Covid - 19 Vaccine Autumn Winter Programme and were informed that since the commencement of the programme, circa 167.8k people have come forward for booster vaccination. HSE Mobile Vaccination Teams have commenced administration of the flu vaccine and Covid-19 Boosters to residents of HIQA Registered Residential Care Facilities for older persons and those who are housebound. The programme is on track to visit all sites by the end of October administering vaccines to consenting and eligible residents. She advised that the uptake for the over 65 eligible population is good, for the 50-64 eligible population and those at high risk is poor and that there is concern in relation to the uptake of vaccines in healthcare workers, and were advised that a communication has been issued to all healthcare workers to increase the uptake.
The Board considered the impact of the public health advisory communications to raise awareness about preventing the spread of Covid 19. It was agreed that ND T&T would follow up on the impact of communications being issued and advise the Board. This related to both infection, prevention and control and boosting immunisation.
There was a query in relation to Evusheld, an antiviral agent that is being used in other countries to help protect high risk individuals from Covid 19, which is not available in Ireland. The CCO provided an update later in the meeting, and advised that there was a HTA process with the company involved and the NCPE have sent additional questions to the company for a response, there has been no financial proposal submitted by the company as yet. The CCO advised the Board that it is hoped that the HTA process will be concluded in the next few weeks, this is reliant on the company submitting outstanding HTA queries.
Cyber Attack - Data Notification Process
The CEO updated the Board in relation to the recruitment process regarding the positions of CTTO and CISO. The job descriptions have been completed and expected to go to the Public Appointment Services this week.
The CEO provided an update to the Board in relation to the Cyber Attack Post Notification Process noting the National Director Operational Performance and Integration was leading out on the project and chairs the Steering Committee in place and gave an outline of the steps being taken. He advised that extensive work has been undertaken in reviewing the exfiltrated data and determining the notifiable subjects as per GDPR regulations, which was followed by a complex verification process. Patients and staff who had some of their personal information illegally accessed and copied during the cyber-attack will be notified by letter. They will then have an opportunity to get advice and further support from the HSE. A robust communication strategy is being prepared to support the notification process, which is scheduled to take place in November 2022,. Due to the numbers of people involved, and the need to support each notification, this will commence later this month and continue in phases over the coming weeks and months.
Winter Plan
The CEO advised the Board that the Winter Plan 2022-2023 was developed in consultation with and 9 approved by the Department of Health and the Minister for Health on 11th October 2022.
The Winter Plan provides for the appropriate, safe and timely care for patients by ensuring, insofar as possible, effective levels of capacity and resources are in place to meet the growth in activity levels, and identify risks in the implementation of the plan. It focuses on continuing to build capacity and capability in developing new services and enhancing existing services as initiated in Winter Plans and National Service Plans in 2020/21 and 2021/2022 respectively, and will focus on delivering a whole system and integrated approach at both a national and local level which aims to facilitate ‘right care, in the right place, at the right time’.
The Board noted that the Winter Plan had not been sent to the Board for its consideration and approval prior to publication and a discussion took place in relation to the process with regards to the issuing of documents regarding strategic planning to the Board in a timely manner, in line with the role of the Board, its list of Reserved matters and its governance responsibilities. Concern was expressed that none of the potentially mitigating controls or other offices involved in managing the Board workplan or agenda had acted to identify or remedy an acknowledged oversight at management level and acted to seek Board approval. The CEO acknowledged and committed to conducting a review with EMT to ensure that such documents are submitted to the Board in a timely manner.
The Board discussed the Winter Plan in particular areas such as recruitment of ED Consultants and the five fundamentals outlined in the plan. Concern was expressed at commitments entered into in a number of aspects of the plan. The Winter Plan as approved by the EMT and published by the Minister was noted by the Board.
Waiting Lists
The CEO provided an update to the Board in relation to Waiting Lists and advised that progress has been made in relation to reducing the number of people on waiting lists, with a focus by the COO and ND Acute Operations in making progress which has seen as of this week the OPD waiting list being reduced. However, despite this reduction, he noted progress against the targets set out in the 2022 Waiting List Action Plan remain challenging. In order to deliver significant improvement by the end of 2022, several targeted actions have been identified and an update in relation to progress against each of these actions was presented in the CEO Report. The CEO advised that work is continuing and a meeting has been arranged with the Minister for Health and Secretary General to discuss further.
A discussion took place in relation to skill sets that could be available in the hospitals and community settings which are perhaps not being fully utilised, which could be of benefit in reducing the waiting list, an example discussed was specifically in relation to Clinical Nurse Specialists (CNS) who don’t have the authority to administer IV drugs, therefore not allowing patients to be able to receive these services at home. ND T&T confirmed she will liaise with the CCO and discuss this matter further.
The Did Not Attend (DNA) Strategy was discussed, which is being tested in three sites at present. The Board noted their concerns that there are a number of reasons why a patient does not attend for their appointment and queried with the EMT if the problems that are in the system are being addressed.
The Board noted the from the CEO report examples of improvements in some hospitals in the decrease in the OPD waiting list that have been achieved compared to the same period last year, and the Board queried how this good practice is shared with other hospitals. The Board was advised that an Achievers List is to be published in November with a list of those hospitals hitting their targets. A high level strategic view will be completed for each hospital, and brought back to the Board.
Disability services
The CEO advised the Board that the implementation of the Progressing Disability Services for Children & Young People (PDS) programme is currently being implemented across the country by HSE Disability teams and partner organisations. This policy supports the reconfiguration of children’s disability services to provide equitable, child and family centred services based on need rather than diagnosis.
The Board discussed their concerns regarding people not being able to access the disability services, and the perceptions that some families feel that they are forgotten about. The age limit to access residential services was queried and the challenges with recruitment and retention of staff in the disability services was highlighted. A request was made for the Disability Roadmap to be shared with the Board.
Ukraine
The CEO advised the Board that the HSE is endeavouring to respond in a planned and coordinated manner to the needs of people fleeing Ukraine and arriving into Ireland. This is part of a much wider cross governmental response and the HSE requires ongoing support and inputs from other government agencies etc. to ensure that we can respond effectively and as appropriate. He advised that HSE Capital & Estates are liaising with other government agencies and organisations and sharing details of vacant buildings and land.
Reconfiguration of Services at Our Lady’s Hospital Navan (OLHN)
The CCO joined the meeting.
The CEO advised the Board that following the Board meeting on the 30 September 2022, and the Special Board meeting on the 5 October 2022, the Chair submitted the OLHN Reconfiguration National 11 Working Group Review and Implementation Plan to the Minister for Health, which the Minister then requested clarity on a range of issues. A response issued to the DoH which included an investment summary in relevant regional healthcare facilities and a Communications plan. He advised that a response from the Minister is awaited, but work is ongoing, led by the ND Acute Operations in relation to implementation of the Reconfiguration Plan.
The Board agreed that the implementation of the Reconfiguration Plan should proceed with ambulance bypass to take place from 12 December 2022, and that the CEO and Chair will continue to deal directly with the Minister. It was agreed that further correspondence should be sent to the Minister setting out the Board’s concerns for patient safety and reinforcing the Board’s decision.
CCO left the meeting.
The Board noted a recent a high court settlement concerning the death of a patient with cervical cancer. It was agreed that the ND of Communications would review how the HSE communicates in an appropriate manner on such cases.
The CEO provided a briefing to the Board on the financial position year to date and stated that the draft revenue I&E financial position at the end of August 2022 shows an YTD deficit of €844.5m or 6.3%. A significant element or €665.4m of this is driven by the direct impact of COVID-19 expenditure with the remainder or €179.1m in Core (ie non COVID-19).
He advised that work is ongoing in the preliminary drafting of the National Service Plan (NSP) 2023, which is required to be submitted within 21 days of receipt of the Letter of Determination from the Department of Health, which was received on 20 October 2022. He noted that the EMT are due to meet next week to look at key issues, and further engagement will be required with the Performance and Delivery Committee and the Board in the preparation and finalisation of the NSP 2023 over the coming weeks.
Scorecard
The Board held a discussion in relation to the Scorecard ratings and KPIs and Ambition Statement not being achieved. It was agreed that the scorings would be reviewed by EMT before resubmission to the Board for sign off. It was also agreed that a more detailed review is to take place at the November Board meeting, and more time on the agenda to be given to discuss the Scorecard.
Fergus Finlay left the meeting.